[1] Durg-induced Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of diagnosis and treatment for drug-induced liver injury: a 2015 update[J]. J Clin Hepatol(临床肝胆病杂志), 2015, 31(11): 1752-1768. [2] CHALASANI NP, MADDUR H, RUSSO MW, et al.ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898. [3] KOIDO M, KAWAKAMI E, FUKUMURA J, et al.Polygenic architecture informs potential vulnerability to drug-induced liver injury[J]. Nature Medicine, 2020, 26(10): 1541-1548. [4] MAO YM.Strengthening transformation research and promoting scientific supervision of drug induced liver injury[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2020, 22(2): 58-61. [5] HOOFNAGLE JH, BJÖRNSSON ES. Drug-induced liver injury - types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273. [6] YU LC, CHEN CW.Pathogenesis of drug-induced liver injury: current understanding and future needs[J]. J Clin Hepatol(临床肝胆病杂志), 2021, 37(11): 2515-2524. [7] SHI YP, WANG SB, LI D, et al.Research progress of drug-induced liver injury[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2018, 24(7): 58-61. [8] ROSENZWEIG P, BROHIER S, ZIPFEL A.The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies[J]. Clin Pharmacol Ther, 1993, 54(5): 578-583. [9] ROSENZWEIG P, BROHIER S, ZIPFEL A.Data on placebo in healthy volunteers: impact of experimental conditions on safety, and on laboratory and physiological variables during phase I trials[J]. Therapie, 1996, 51(4): 356-357. [10] SIBILLE M, DEIGAT N, DURIEU I, et al.Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials[J]. Eur J Clin Pharmacol, 1999, 55(1): 13-19. [11] PURKINS L, LOVE ER, EVE MD, et al.The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a phase I unit[J]. Br J Clin Pharmacol, 2004, 57(2): 199-208. [12] TEMPLE R.Hy's law: predicting serious hepatotoxicity[J]. Pharmacoepidemiol Drug Saf, 2006, 15(4): 241-243. [13] BÉNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol, 1990, 11(2): 272-276. [14] NEUSCHWANDER-TETRI BA, CALDWELL SH.Nonalcoholic steatohepatitis: summary of an AASLD single topic conference[J]. Hepatology, 2003, 37(5): 1202-1219. [15] MAKAR GA, WEINER MG, KIMMEL SE, et al.Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population[J]. Pharmacoepidemiol Drug Saf, 2008, 17(1): 43-51. [16] WEIL JG, BAINS C, LINKE A, et al.Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease[J]. Regul Toxicol Pharmacol, 2008, 52(2): 85-88. [17] SAUKKONEN JJ, COHN DL, JASMER RM, et al.An official ATS statement: hepatotoxicity of antituberculosis therapy[J]. Am J Respir Crit Care Med, 2006, 174(8): 935-952. [18] AITHAL GP, WATKINS PB, ANDRADE RJ, et al.Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther, 2011,89(6): 806-815. [19] CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al.ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966, 967. [20] EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. [21] Group AcbaCW. Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting[R/OL]. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS), 2020. https://cioms.ch/wp-content/uploads/2020/06/CIOMS_DILI_Web_16Jun2020.pdf. [22] DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al.Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines[J]. Hepatol Int, 2021, 15(2): 258-282. [23] ZHANG HL, XU LL, XIE YJ, et al.201 Cases of drug-induced liver injury in children[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(10): 715-719. [24] LI J, HE LM, ZHANG HX, et al.Analysis of 70 cases of children with drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(7): 431-436. [25] Professional Committee of clinical examination standards of the Ministry of health. WS/T 404.1-2012. Reference intervals of clinical biochemistry tests commonly used[S]. Ministry of Health of the People's Republic of China, 2021. [26] Beijing Children's Hospital Affiliated to Capital Medical University, the First Affiliated Hospital of China Medical University, Clinical laboratory center of National Health Commission, et al. WS/T 780-2021. Reference intervals of clinical biochemistry tests commonly used for children[S]. State Health Commission of the People's Republic of China, 2021. [27] NI X, SONG W, PENG X, et al.Pediatric reference intervals in China (PRINCE): design and rationale for a large, multicenter collaborative cross-sectional study[J]. Science Bulletin, 2018, 63(24): 1626-1634. |